PapersFlow Research Brief
Sarcoidosis and Beryllium Toxicity Research
Research Guide
What is Sarcoidosis and Beryllium Toxicity Research?
Sarcoidosis and Beryllium Toxicity Research is a field studying the clinical characteristics, diagnosis, management, and genetic susceptibility of sarcoidosis, including cardiac, pulmonary, and neurosarcoidosis, alongside imaging techniques and therapies, with beryllium toxicity noted in differential diagnosis of granulomatous lung diseases.
This research cluster includes 44,108 works on sarcoidosis, focusing on granulomatous inflammation, genetic susceptibility, and organ-specific manifestations such as cardiac, pulmonary, and neurosarcoidosis. Key studies address diagnosis and management using imaging and therapeutic interventions. Growth rate over the past 5 years is not available in the provided data.
Topic Hierarchy
Research Sub-Topics
Cardiac Sarcoidosis Diagnosis
This sub-topic covers advanced imaging modalities like PET-CT and MRI for detecting cardiac involvement in sarcoidosis, along with clinical diagnostic criteria and biopsy techniques. Researchers study prognostic markers and risk stratification to differentiate from other cardiomyopathies.
Pulmonary Sarcoidosis Management
This sub-topic examines corticosteroid therapies, immunosuppressive agents, and anti-fibrotic drugs for pulmonary manifestations, including progression to fibrosis. Researchers investigate treatment response predictors and long-term outcomes in interstitial lung disease.
Neurosarcoidosis Clinical Features
This sub-topic focuses on neurological manifestations such as cranial neuropathies, aseptic meningitis, and hypothalamic-pituitary involvement. Researchers analyze CSF biomarkers, MRI patterns, and differential diagnosis from other granulomatous diseases.
Sarcoidosis Genetic Susceptibility
This sub-topic explores HLA associations, GWAS-identified loci like BTNL2, and ethnic variations in disease risk. Researchers study gene-environment interactions and heritability in familial clustering.
Beryllium Sensitization Chronic Disease
This sub-topic investigates lymphocyte proliferation tests for diagnosis, granuloma formation parallels to sarcoidosis, and occupational exposure thresholds. Researchers compare clinical courses and treatment responses between beryllium-induced and idiopathic sarcoidosis.
Why It Matters
Research on sarcoidosis informs diagnosis and treatment of granulomatous diseases affecting lungs, heart, and nervous system, with direct applications in clinical management. Iannuzzi et al. (2007) in "Sarcoidosis" detailed incidence variations by race and age, noting higher rates in people under 50 and differences due to environmental exposures and HLA types, aiding targeted screening. The "Statement on Sarcoidosis" (1999) provides consensus guidelines used in respiratory care for over 1873 citations, improving patient outcomes in pulmonary cases. Studies like "Wegener Granulomatosis: An Analysis of 158 Patients" by Hoffman et al. (1992) highlight cyclophosphamide and glucocorticoids achieving high remission rates in related granulomatous conditions, reducing morbidity in 158 analyzed cases.
Reading Guide
Where to Start
"Sarcoidosis" by Iannuzzi et al. (2007), as it provides a foundational overview of epidemiology, clinical features, and genetic factors in 1914 citations.
Key Papers Explained
Iannuzzi et al. (2007) "Sarcoidosis" establishes core clinical and genetic aspects, cited 1914 times; the "Statement on Sarcoidosis" (1999) builds with diagnostic consensus (1873 citations); Hoffman et al. (1992) "Wegener Granulomatosis: An Analysis of 158 Patients" (2855 citations) connects via shared granulomatous pathology and cyclophosphamide therapy insights.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current efforts focus on organ-specific management in cardiac and neurosarcoidosis, with no recent preprints or news available; emphasis remains on imaging and genetic studies from established papers.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | 2012 Revised International Chapel Hill Consensus Conference No... | 2012 | Arthritis & Rheumatism | 6.4K | ✓ |
| 2 | Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibr... | 2014 | New England Journal of... | 4.4K | ✓ |
| 3 | Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ER... | 2018 | American Journal of Re... | 3.8K | ✕ |
| 4 | Wegener Granulomatosis: An Analysis of 158 Patients | 1992 | Annals of Internal Med... | 2.9K | ✕ |
| 5 | Nintedanib in Progressive Fibrosing Interstitial Lung Diseases | 2019 | New England Journal of... | 2.2K | ✓ |
| 6 | The American College of Rheumatology 1990 criteria for the cla... | 1990 | Arthritis & Rheumatism | 2.0K | ✕ |
| 7 | Sarcoidosis | 2007 | New England Journal of... | 1.9K | ✕ |
| 8 | Idiopathic pulmonary fibrosis | 2017 | The Lancet | 1.9K | ✕ |
| 9 | Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis | 2016 | Circulation | 1.9K | ✓ |
| 10 | Statement on Sarcoidosis | 1999 | American Journal of Re... | 1.9K | ✕ |
Frequently Asked Questions
What is sarcoidosis?
Sarcoidosis is a multisystem granulomatous disorder affecting people of all racial and ethnic groups, usually before age 50. Iannuzzi et al. (2007) in "Sarcoidosis" report worldwide incidence variations due to environmental exposures, case surveillance, and predisposing HLA types. It manifests in pulmonary, cardiac, and neurosarcoidosis forms.
How is sarcoidosis diagnosed?
Diagnosis involves clinical characteristics, imaging, and exclusion of mimics like beryllium toxicity. The "Statement on Sarcoidosis" (1999) outlines consensus criteria for respiratory cases. Genetic susceptibility and biopsy confirm granulomatous inflammation.
What are management strategies for sarcoidosis?
Therapy includes glucocorticoids and immunosuppressants for organ involvement. Hoffman et al. (1992) in "Wegener Granulomatosis: An Analysis of 158 Patients" showed cyclophosphamide with glucocorticoids induced remission in granulomatous diseases. Monitoring pulmonary, cardiac, and neurosarcoidosis guides interventions.
What role does genetic susceptibility play in sarcoidosis?
Genetic factors like HLA types predispose to sarcoidosis. Iannuzzi et al. (2007) in "Sarcoidosis" link HLA variations to incidence differences across populations. This informs risk assessment in clinical practice.
How does beryllium toxicity relate to sarcoidosis research?
Beryllium toxicity causes chronic granulomatous lung disease mimicking pulmonary sarcoidosis. Research differentiates it via exposure history and lymphocyte proliferation tests. Sarcoidosis studies emphasize excluding occupational exposures in diagnosis.
What imaging techniques are used in sarcoidosis?
Imaging assesses cardiac, pulmonary, and neurosarcoidosis involvement. Consensus papers like the "Statement on Sarcoidosis" (1999) recommend chest imaging and echocardiography. These detect granulomas non-invasively.
Open Research Questions
- ? How can genetic susceptibility markers improve early diagnosis of cardiac sarcoidosis?
- ? What therapeutic interventions best manage neurosarcoidosis progression?
- ? Which imaging modalities most accurately distinguish pulmonary sarcoidosis from beryllium toxicity?
- ? What environmental factors beyond beryllium exposure trigger granulomatous inflammation in sarcoidosis?
- ? How do treatment responses in sarcoidosis compare to those in related vasculitides like Wegener granulomatosis?
Recent Trends
The field encompasses 44,108 works with no specified 5-year growth rate; highly cited papers like Jennette et al. "2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides" (6357 citations) refine granulomatous disease classification, while Richeldi et al. (2014) "Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis" (4357 citations) explores antifibrotic therapies relevant to pulmonary sarcoidosis overlaps; no recent preprints or news reported.
2012Research Sarcoidosis and Beryllium Toxicity Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Sarcoidosis and Beryllium Toxicity Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers